Correction: Overcoming chemoresistance in esophageal cancer with synergistic strategies - Summary - MDSpire

Correction: Overcoming chemoresistance in esophageal cancer with synergistic strategies

  • By

  • Chunxiao Gao

  • Ting Zhang

  • Guangyuan Li

  • Weishan Zhang

  • Honglin Chen

  • Diefei Li

  • Jixuan Xu

  • Mengxue Li

  • Ruihong Wang

  • Yamin Xing

  • Jian Zhan

  • Zhentai Ren

  • Xia Xue

  • Wulong Liang

  • Xiangdong Sun

  • Xiaojuan Zhang

  • Xinfeng Liang

  • Hongqiao Zhan

  • Zisen Zhang

  • Xiufeng Chu

  • July 3, 2026

  • 0 min

Share

Objective:

To correct errors in the previously published article regarding chemoresistance strategies in esophageal cancer.

Approach:
  • Correction of Text Errors: Corrections were made to the introduction and various sections to fix grammatical errors and citation inaccuracies.
  • Supplemental Material Publication: Supplemental Material, specifically Supplementary Table 1, was published after being omitted in the original article.
Key Findings:
  • Chemotherapy is a fundamental component of current combination therapies.
  • CD8+ T cells are functionally impaired in esophageal cancer due to immune checkpoint molecules.
  • P-gp inhibitors and PARP inhibitors are under development to overcome chemoresistance.
Interpretation:

The corrections clarify the role of chemotherapy and the mechanisms of chemoresistance in esophageal cancer.

Limitations:
  • The article does not provide new experimental data but corrects previously published content.
  • The applicability of findings from other malignancies to esophageal cancer remains to be fully validated.
Conclusion:

The corrections enhance the accuracy of the information regarding chemoresistance strategies in esophageal cancer.

Sources:

Original Source(s)

Correction: Overcoming chemoresistance in esophageal cancer with synergistic strategies

  • by Chunxiao Gao, Ting Zhang, Guangyuan Li, Weishan Zhang, Honglin Chen, Diefei Li, Jixuan Xu, Mengxue Li, Ruihong Wang, Yamin Xing, Jian Zhan, Zhentai Ren, Xia Xue, Wulong Liang, Xiangdong Sun, Xiaojuan Zhang, Xinfeng Liang, Hongqiao Zhan, Zisen Zhang, Xiufeng Chu

  • July 3, 2026

Related Content

Factors associated with relapse/progression in pediatric trunk and extremity rhabdomyosarcoma

A prediction model for urological tumor metastasis using liquid biopsy-derived biomarkers

Microbiome dysbiosis and its modulation in cancer development, prevention and therapy